Earlier the better: Convalescent plasma

Aaron A.R. Tobian; Beth H. Shaz

doi:10.1182/BLOOD.2020007638

Earlier the better: Convalescent plasma

Aaron A.R. Tobian, Beth H. Shaz

School of Medicine

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

In the current issue of Blood, Xia et al evaluate the use of convalescent plasma for the treatment of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19).^1,2 SARS-CoV-2 has spurred a global crisis. To date, there are limited treatment options for COVID-19 and no proven prophylactic therapies for those who have been exposed to SARS-CoV-2.

Original language	English (US)
Pages (from-to)	652-654
Number of pages	3
Journal	Blood
Volume	136
Issue number	6
DOIs	https://doi.org/10.1182/BLOOD.2020007638
State	Published - Aug 2020

ASJC Scopus subject areas

Biochemistry
Immunology
Hematology
Cell Biology

Access to Document

10.1182/BLOOD.2020007638

Cite this

@article{eac2d17d8e56418d905a391045842fca,

title = "Earlier the better: Convalescent plasma",

abstract = "In the current issue of Blood, Xia et al evaluate the use of convalescent plasma for the treatment of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19).1,2 SARS-CoV-2 has spurred a global crisis. To date, there are limited treatment options for COVID-19 and no proven prophylactic therapies for those who have been exposed to SARS-CoV-2.",

author = "Tobian, {Aaron A.R.} and Shaz, {Beth H.}",

note = "Publisher Copyright: {\textcopyright} 2020 by The American Society of Hematology.",

year = "2020",

month = aug,

doi = "10.1182/BLOOD.2020007638",

language = "English (US)",

volume = "136",

pages = "652--654",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

number = "6",

}

TY - JOUR

T1 - Earlier the better

T2 - Convalescent plasma

AU - Tobian, Aaron A.R.

AU - Shaz, Beth H.

PY - 2020/8

Y1 - 2020/8

N2 - In the current issue of Blood, Xia et al evaluate the use of convalescent plasma for the treatment of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19).1,2 SARS-CoV-2 has spurred a global crisis. To date, there are limited treatment options for COVID-19 and no proven prophylactic therapies for those who have been exposed to SARS-CoV-2.

AB - In the current issue of Blood, Xia et al evaluate the use of convalescent plasma for the treatment of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19).1,2 SARS-CoV-2 has spurred a global crisis. To date, there are limited treatment options for COVID-19 and no proven prophylactic therapies for those who have been exposed to SARS-CoV-2.

UR - http://www.scopus.com/inward/record.url?scp=85089170908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089170908&partnerID=8YFLogxK

U2 - 10.1182/BLOOD.2020007638

DO - 10.1182/BLOOD.2020007638

M3 - Review article

C2 - 32761223

AN - SCOPUS:85089170908

SN - 0006-4971

VL - 136

SP - 652

EP - 654

JO - Blood

JF - Blood

IS - 6

ER -

Earlier the better: Convalescent plasma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this